Trials are ongoing to determine if Aromatase inhibitors are superior to Tamoxifen in the adjuvant setting after breast conserving surgery for DCIS (NSABP B-35 and IBIS II). Here, CYP19A1 is linked to ductal breast carcinoma in situ.